Kodiak Sciences Inc KOD:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 02/26/21 EST
129.01UNCH (UNCH)
Volume
9,145
Close
129.01quote price arrow up+7.93 (+6.55%)
Volume
354,747
52 week range
35.49 - 171.21

...

Loading . . .

KEY STATS

  • Open122.50
  • Day High133.34
  • Day Low120.38
  • Prev Close121.08
  • 52 Week High171.21
  • 52 Week High Date02/10/21
  • 52 Week Low35.49
  • 52 Week Low Date03/18/20
  • Market Cap6.444B
  • Shares Out49.95M
  • 10 Day Average Volume0.36M
  • Dividend-
  • Dividend Yield-
  • Beta1.51
  • 1 Year % Change124.01

RATIOS/PROFITABILITY

  • EPS (TTM)-2.32
  • P/E (TTM)-55.66
  • Fwd P/E (NTM)-33.69
  • EBITDA (MRQ)-104.899M
  • ROE (MRQ)-59.82%
  • Revenue (MRQ)0.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date03/15/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Kodiak Sciences Inc News

There is no recent news for this security.

Latest KOD News From Our Partners

February 10, 2021

QUOTE FINDER

Profile

MORE
Kodiak Sciences Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing therapeutics to treat ophthalmic diseases. The Company’s Antibody Biopolymer Conjugate (ABC) platform focuses on merging the fields of antibody-based and chemistry-based therapies. The Company in addition to its lead product candidate, KSI-301, is a molecule for age-related macular degeneration and diabetic retinopathy. The Company has leveraged its ABC platform to build a...
Victor Perlroth M.D.
Chairman
John Borgeson
Chief Financial Officer
Address
1200 PAGE MILL RD
Palo Alto, CA
94304
United States